About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNANCT06738381

Digital Secondary Prevention After Atherosclerotic Cardiovascular Disease

Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide and in Norway. Approximately 50% of the patients admitted to hospitals with an acute ASCVD e...

Lead sponsor: Vestre Viken Hospital Trust•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

John Munkhaugen, MD, PhD

CONTACT

+4797524194 johmun@vestreviken.no

Sponsors

Lead Sponsor

Vestre Viken Hospital Trust

Collaborators

University of Oslo

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Aged \>=18 years and signed informed consent and expected cooperation according to ICH/GCP and national/local regulations
•Hospitalised with an planned or unplanned ASCVD event and/or established atherosclerosis
•Access to a smartphone or tablet

Exclusion Criteria

•Any condition or situation, that in the investigator's opinion could put the subject at significant risk, confound the study results, interfere significantly with the subject participation in the study, or rendering informed consent unfeasible not limited to: cognitive impairment, seizure disorders, active suicidal intent or plans, substance or alcohol dependence, psychotic disease, major depressive disorders or bipolar disorders, receiving concurrent psychological treatments, and ongoing night shift work.
•Short life expectancy (\<12 months) due to end-organ (i.e COPD 4, CKD 4/5) or malignant diseases
•Clinically significant symptoms of anxiety and depression (HADS A and/or HADS-D score ≥8)
•Not being able to understand Norwegian.

Related studies

Enrolling By Invitation

Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study

NCT07363980 · Rheumatoid Arthritis, Atherosclerotic Ischemic Disease, and more

Enrolling By InvitationNA

A Study of Cerebral Perfusion With tDCS in Chronic Hypoperfusion

NCT06477107 · Moyamoya Syndrome, Moyamoya Disease, and more

COMPLETEDPhase 3

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

NCT05004675 · Hypercholesterolemia, Atherosclerotic Ischemic Disease

Carotid Plaque-Burden Scale and Outcomes. A Real Life Study

NCT06187532 · Atheroscleroses, Cerebral, Carotid Plaque

Effect Of Semaglutide In Coronary Atheroma Plaque

NCT05071417 · Atheroscleroses, Coronary

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 21, 2025Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment300

Start dateFeb 2025

Last updatedFeb 21, 2025

Condition

Atheroscleroses, Coronary Atheroscleroses, Cerebral Atherosclerotic Ischemic Disease

Locations shown

Vestre Viken Trust Drammen hospital

Drammen, Buskerud

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 21, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions